Published in J Clin Pharmacol on December 14, 2011
Polypharmacy in the HIV-infected older adult population. Clin Interv Aging (2013) 0.83
Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr (2014) 0.80
Drug interactions and antiretroviral drug monitoring. Curr HIV/AIDS Rep (2014) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med (2006) 2.83
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
Concern Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest (2012) 2.23
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10
Early effect of tidal volume on lung injury biomarkers in surgical patients with healthy lungs. Anesthesiology (2014) 2.06
Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology (2006) 2.04
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.78
Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother (2011) 1.77
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS (2002) 1.58
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr (2008) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications (2009) 1.26
Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr (2008) 1.24
HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin Chem (2007) 1.22
Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv (2004) 1.19
Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.16
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal (2013) 1.11
Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation (2005) 1.10
Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. Cancer Res (2009) 1.09
Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia. J Vasc Surg (2006) 1.09
Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal Biochem (2007) 1.09
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother (2010) 1.06
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr (2014) 1.05
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol (2009) 1.04
Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. JPEN J Parenter Enteral Nutr (2003) 1.01
Atazanavir-containing renal calculi in an HIV-infected patient. AIDS (2007) 1.01
Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells. Pharm Res (2002) 1.00
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res (2010) 1.00
Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. Cardiovasc Res (2012) 0.99
CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther (2003) 0.99
Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol (2013) 0.99
Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol (2012) 0.98
Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit (2008) 0.98
Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet (2003) 0.97
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother (2013) 0.97
Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. AIDS Patient Care STDS (2011) 0.97
Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr (2015) 0.96
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol (1985) (2005) 0.95
Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism (2008) 0.94
Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron Exp Nephrol (2009) 0.94
Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr (2013) 0.93
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol (2011) 0.93
A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 0.92
Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv (2010) 0.91
Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared. Rapid Commun Mass Spectrom (2011) 0.90
Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther (2011) 0.90
Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol (2009) 0.90
Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol (2013) 0.90
Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res (2010) 0.90
Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res Hum Genet (2010) 0.89
Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics (2007) 0.89
Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit (2005) 0.89
Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention (2013) 0.88
Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol (2007) 0.88
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses (2014) 0.87
Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther (2002) 0.87
Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Analg (2009) 0.87
Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol (2010) 0.87
Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.87
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit (2016) 0.86
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J (2015) 0.86
A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses (2012) 0.86
Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom (2007) 0.86
Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.85
Proteomics and metabolomics in renal transplantation-quo vadis? Transpl Int (2012) 0.85
Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit (2004) 0.85
Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT. Transpl Int (2004) 0.85
Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr (2015) 0.84
Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Investig Drugs (2003) 0.84
Acute pancreatitis in HIV-infected patients: are etiologies changing since the introduction of protease inhibitor therapy? Pancreas (2003) 0.84
The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Xenotransplantation (2005) 0.84
The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv (2008) 0.84
Identification and characterization of a bacterial cytochrome P450 for the metabolism of diclofenac. Appl Microbiol Biotechnol (2009) 0.83
Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos (2010) 0.83
Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study. Int J Cancer (2011) 0.83
Enhanced leukocyte HIF-1alpha and HIF-1 DNA binding in humans after rapid ascent to 4300 m. Free Radic Biol Med (2009) 0.83
Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol (2008) 0.83
Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol (2013) 0.83
Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab (2002) 0.82
Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol (2010) 0.82
Fibronectin-integrin signaling is required for L-glutamine's protection against gut injury. PLoS One (2012) 0.82
Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant (2007) 0.82
Cyclosporine can increase isoflurane MAC. Anesth Analg (2002) 0.82
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS (2004) 0.82
Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Release (2005) 0.82
A metabonomic and proteomic analysis of changes in IMCD3 cells chronically adapted to hypertonicity. Nephron Physiol (2008) 0.82